{"id":18707,"date":"2022-07-12T10:22:00","date_gmt":"2022-07-12T08:22:00","guid":{"rendered":"https:\/\/fundaciongaem.org\/el-58-de-persones-tractades-amb-aubagio-sense-simptomes-despres-de-2-anys-2\/"},"modified":"2022-07-12T10:22:00","modified_gmt":"2022-07-12T08:22:00","slug":"el-58-de-persones-tractades-amb-aubagio-sense-simptomes-despres-de-2-anys-2","status":"publish","type":"post","link":"https:\/\/fundaciongaem.org\/ca\/el-58-de-persones-tractades-amb-aubagio-sense-simptomes-despres-de-2-anys-2\/","title":{"rendered":"El 58 % de persones tractades amb Aubagio sense s\u00edmptomes despr\u00e9s de 2 anys"},"content":{"rendered":"<h3>M\u00e9s de la meitat de les persones amb esclerosi m\u00faltiple tractades amb Aubagio (teriflunomida) no van mostrar evid\u00e8ncia d&#8217;activitat de la malaltia despr\u00e9s de dos anys de tractament<\/h3>\n<p>S\u00f3n els resultats de l&#8217;estudi, &#8220;<strong>Evoluci\u00f3 de l&#8217;\u00fas de teriflunomida en l&#8217;esclerosi m\u00faltiple: una experi\u00e8ncia del m\u00f3n real<\/strong>&#8220;, realitzat a It\u00e0lia i publicat en el <span class=\"hiddenSpellError\">Journal<\/span> <span class=\"hiddenSpellError\">of<\/span> <span class=\"hiddenSpellError\">the<\/span> <span class=\"hiddenSpellError\">Neurological<\/span> <span class=\"hiddenSpellError\">Sciences<\/span>.<\/p>\n<p><a href=\"https:\/\/cima.aemps.es\/cima\/dochtml\/p\/113838002\/P_113838002.html\"><span class=\"hiddenSpellError\">Aubagio<\/span><\/a> \u00e9s una ter\u00e0pia oral modificadora de la malaltia que ha estat aprovada des de 2013 a la Uni\u00f3 Europea per a tractar a adults amb <a href=\"https:\/\/fundaciongaem.org\/ca\/que-es-la-esclerosis-multiple\/\">EM remitent-recurrent (<span class=\"hiddenSpellError\">EMRR<\/span>)<\/a>. Ho comercialitza Sanofi, que no va participar en el present estudi.<\/p>\n<p>Els cient\u00edfics de la Universitat de C\u00e0ller van analitzar als pacients que van comen\u00e7ar el tractament amb <span class=\"hiddenSpellError\">Aubagio<\/span> en la seva cl\u00ednica entre 2016 i 2020. L&#8217;an\u00e0lisi va incloure dades de 319 pacients: al voltant de dos ter\u00e7os eren dones i l&#8217;edat mitjana rondava els <span class=\"hiddenGreenError\">40<\/span> anys.<\/p>\n<p>La majoria dels pacients (79%) havien canviat a <span class=\"hiddenSpellError\">Aubagio<\/span> des d&#8217;un tractament diferent per a <span class=\"hiddenGrammarError\">l&#8217;EM<\/span>, mentre que el 21% restant no havien rebut tractament previ, cosa que significa que <span class=\"hiddenSpellError\">Aubagio<\/span> va ser la primera ter\u00e0pia per a <span class=\"hiddenGrammarError\">la EM<\/span> que van provar.<\/p>\n<p>A fins de 2020, 240 (75,2%) dels pacients encara rebien tractament amb <span class=\"hiddenSpellError\">Aubagio<\/span> despr\u00e9s d&#8217;una mitjana de seguiment de gaireb\u00e9 quatre anys (45,7 mesos). Entre els quals van deixar de prendre <span class=\"hiddenSpellError\">Aubagio<\/span>, la mitjana de la durada del tractament va ser de poc menys de dos anys, i poc m\u00e9s d&#8217;un ter\u00e7 (35,4%) va citar la falta d&#8217;efic\u00e0cia com a motiu per a deixar-ho.<\/p>\n<p>&nbsp;<\/p>\n<p style=\"padding-left: 40px;\"><a href=\"https:\/\/fundaciongaem.org\/ca\/\">Fundaci\u00f3 <span class=\"hiddenSpellError\">GAEM<\/span><\/a> i<strong>mpulsa la innovaci\u00f3 biom\u00e8dica per a trobar una cura per a l&#8217;esclerosi m\u00faltiple<\/strong> i millorar la vida de m\u00e9s de 55.000 persones a Espanya. <a href=\"https:\/\/fundaciongaem.org\/ca\/colabora\/\">Dona suport a la seva labor de recerca i sensibilitzaci\u00f3<\/a> sobre aquesta malaltia que no t\u00e9 cura.<\/p>\n<p>&nbsp;<\/p>\n<p>Les dades d&#8217;efic\u00e0cia estaven disponibles per a 204 pacients que havien pres Aubagio durant almenys dos anys. D&#8217;aquests, m\u00e9s de la meitat (58,8%) no va mostrar evid\u00e8ncia d&#8217;activitat de la malaltia (<a href=\"https:\/\/rochepacientes.es\/esclerosis-multiple\/concepto-neda.html\">NEDA<\/a>) durant dos anys, cosa que significa que no van tenir recaigudes, ni empitjorament de la discapacitat, ni signes de nou mal inflamatori en les resson\u00e0ncies magn\u00e8tiques. NEDA tamb\u00e9 va ser aconseguit per m\u00e9s de la meitat dels pacients (56,8%) que van romandre en tractament durant tres anys.<\/p>\n<p>La probabilitat de NEDA al cap de dos anys va ser m\u00e9s alta per als quals eren m\u00e9s joves i els que tenien puntuacions de discapacitat m\u00e9s lleus i menys recaigudes abans de comen\u00e7ar amb Aubagio, segons van mostrar les an\u00e0lisis estad\u00edstiques.<\/p>\n<p>&#8220;<em>El nostre estudi va trobar que l&#8217;edat i el nivell de discapacitat es van confirmar com a factors que influeixen en la resposta al tractament, d&#8217;acord amb les dades de la literatura actual que indiquen que &#8216;el tractament primerenc \u00e9s millor que el tard\u00e0, per\u00f2 tardar \u00e9s millor que mai&#8217;<\/em>&#8220;, van escriure els investigadors.<\/p>\n<p>Les an\u00e0lisis tamb\u00e9 van mostrar que la demografia dels pacients que van comen\u00e7ar amb Aubagio va canviar alguna cosa durant els cinc anys de l&#8217;estudi. Espec\u00edficament, els investigadors van notar que la proporci\u00f3 de pacients sense tractament previ va augmentar d&#8217;aproximadament un 10% en 2016 a aproximadament un 30% en 2020.<\/p>\n<p>La proporci\u00f3 de pacients que eren dones menors de 45 anys, la qual cosa es coneix com a &#8220;edat f\u00e8rtil&#8221;, tamb\u00e9 va augmentar, al voltant del 20% en 2016 a al voltant del 30% en 2020. No es recomana l&#8217;\u00fas d&#8217;Aubagio durant l&#8217;embar\u00e0s, i es recomana que qualsevol persona que podria quedar embarassada utilitzi m\u00e8todes anticonceptius efectius mentre estigui en tractament. Els investigadors van notar que el 82,3% de les dones menors de 45 anys en aquest estudi ja tenien fills abans de comen\u00e7ar amb Aubagio.<\/p>\n<p>\u201c<em>L&#8217;\u00fas de Aubagio s&#8217;ha incrementat progressivament en la pr\u00e0ctica cl\u00ednica, particularment per a pacients recents i dones joves, despr\u00e9s d&#8217;un adequat proc\u00e9s de presa de decisions compartida amb el neur\u00f2leg tractant i amb anticoncepci\u00f3 correcta<\/em>\u201d, van concloure els investigadors.<\/p>\n<p>&nbsp;<\/p>\n<p>Llegir <a href=\"https:\/\/multiplesclerosisnewstoday.com\/news-posts\/2022\/06\/07\/more-than-half-ms-patients-aubagio-after-2-years-show-neda\/?utm_source=MS&amp;utm_campaign=183982ac72-RSS_EMAIL_CAMPAIGN&amp;utm_medium=email&amp;utm_term=0_b5fb7a3dae-183982ac72-73457897\">article complet en MSNews Today<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u00e1s de la mitad de las personas con esclerosis m\u00faltiple tratadas con Aubagio (teriflunomida) no mostraron evidencia de actividad de la enfermedad despu\u00e9s de dos a\u00f1os de tratamiento<\/p>\n","protected":false},"author":1,"featured_media":18237,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[212],"tags":[1584,2473,1542,2412],"class_list":["post-18707","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-em-i-nmo","tag-esclerosismultiple","tag-aubagio","tag-esclerosis-multiple","tag-teriflunomida","category-212","description-off"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>El 58 % de persones tractades amb Aubagio sense s\u00edmptomes despr\u00e9s de 2 anys - GAEM (Grupo de Afectados de Esclerosis M\u00faltiple)<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fundaciongaem.org\/ca\/el-58-de-persones-tractades-amb-aubagio-sense-simptomes-despres-de-2-anys-2\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"El 58 % de persones tractades amb Aubagio sense s\u00edmptomes despr\u00e9s de 2 anys - GAEM (Grupo de Afectados de Esclerosis M\u00faltiple)\" \/>\n<meta property=\"og:description\" content=\"\u00e1s de la mitad de las personas con esclerosis m\u00faltiple tratadas con Aubagio (teriflunomida) no mostraron evidencia de actividad de la enfermedad despu\u00e9s de dos a\u00f1os de tratamiento\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fundaciongaem.org\/ca\/el-58-de-persones-tractades-amb-aubagio-sense-simptomes-despres-de-2-anys-2\/\" \/>\n<meta property=\"og:site_name\" content=\"GAEM (Grupo de Afectados de Esclerosis M\u00faltiple)\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/FundacioGaem\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-12T08:22:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fundaciongaem.org\/wp-content\/uploads\/2024\/03\/Teriflunomide_3D_ball-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"631\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"PROGRAMADOR\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@fundaciongaem\" \/>\n<meta name=\"twitter:site\" content=\"@fundaciongaem\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"PROGRAMADOR\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/el-58-de-persones-tractades-amb-aubagio-sense-simptomes-despres-de-2-anys-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/el-58-de-persones-tractades-amb-aubagio-sense-simptomes-despres-de-2-anys-2\\\/\"},\"author\":{\"name\":\"PROGRAMADOR\",\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/#\\\/schema\\\/person\\\/093d963705cb588ce96ffe4a15bde10c\"},\"headline\":\"El 58 % de persones tractades amb Aubagio sense s\u00edmptomes despr\u00e9s de 2 anys\",\"datePublished\":\"2022-07-12T08:22:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/el-58-de-persones-tractades-amb-aubagio-sense-simptomes-despres-de-2-anys-2\\\/\"},\"wordCount\":713,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/el-58-de-persones-tractades-amb-aubagio-sense-simptomes-despres-de-2-anys-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fundaciongaem.org\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/Teriflunomide_3D_ball-1.png\",\"keywords\":[\"#esclerosism\u00faltiple\",\"Aubagio\",\"Esclerosis M\u00faltiple\",\"teriflunomida\"],\"articleSection\":[\"EM \\\/ NMO\"],\"inLanguage\":\"ca\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/el-58-de-persones-tractades-amb-aubagio-sense-simptomes-despres-de-2-anys-2\\\/\",\"url\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/el-58-de-persones-tractades-amb-aubagio-sense-simptomes-despres-de-2-anys-2\\\/\",\"name\":\"El 58 % de persones tractades amb Aubagio sense s\u00edmptomes despr\u00e9s de 2 anys - GAEM (Grupo de Afectados de Esclerosis M\u00faltiple)\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/el-58-de-persones-tractades-amb-aubagio-sense-simptomes-despres-de-2-anys-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/el-58-de-persones-tractades-amb-aubagio-sense-simptomes-despres-de-2-anys-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fundaciongaem.org\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/Teriflunomide_3D_ball-1.png\",\"datePublished\":\"2022-07-12T08:22:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/el-58-de-persones-tractades-amb-aubagio-sense-simptomes-despres-de-2-anys-2\\\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/el-58-de-persones-tractades-amb-aubagio-sense-simptomes-despres-de-2-anys-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/el-58-de-persones-tractades-amb-aubagio-sense-simptomes-despres-de-2-anys-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/fundaciongaem.org\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/Teriflunomide_3D_ball-1.png\",\"contentUrl\":\"https:\\\/\\\/fundaciongaem.org\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/Teriflunomide_3D_ball-1.png\",\"width\":1024,\"height\":631},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/el-58-de-persones-tractades-amb-aubagio-sense-simptomes-despres-de-2-anys-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/inicio\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"El 58 % de persones tractades amb Aubagio sense s\u00edmptomes despr\u00e9s de 2 anys\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/#website\",\"url\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/\",\"name\":\"GAEM (Grupo de Afectados de Esclerosis M\u00faltiple)\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/#organization\",\"name\":\"GAEM (Grupo de Afectados de Esclerosis M\u00faltiple)\",\"url\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/fundaciongaem.org\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/LOGO-2.png\",\"contentUrl\":\"https:\\\/\\\/fundaciongaem.org\\\/wp-content\\\/uploads\\\/2023\\\/11\\\/LOGO-2.png\",\"width\":354,\"height\":132,\"caption\":\"GAEM (Grupo de Afectados de Esclerosis M\u00faltiple)\"},\"image\":{\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/FundacioGaem\\\/\",\"https:\\\/\\\/x.com\\\/fundaciongaem\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/2454646\",\"https:\\\/\\\/www.instagram.com\\\/fundaciongaem\\\/cebook.com\\\/FundacioGaem\\\/\",\"https:\\\/\\\/www.youtube.com\\\/user\\\/fundaciogaem\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/#\\\/schema\\\/person\\\/093d963705cb588ce96ffe4a15bde10c\",\"name\":\"PROGRAMADOR\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b57ee1544b5750bf1116758aec83af4d7c9709bbc2131c9e1568d92ff8d2e28b?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b57ee1544b5750bf1116758aec83af4d7c9709bbc2131c9e1568d92ff8d2e28b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b57ee1544b5750bf1116758aec83af4d7c9709bbc2131c9e1568d92ff8d2e28b?s=96&d=mm&r=g\",\"caption\":\"PROGRAMADOR\"},\"sameAs\":[\"https:\\\/\\\/fundaciongaem.org\"],\"url\":\"https:\\\/\\\/fundaciongaem.org\\\/ca\\\/author\\\/gaem\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"El 58 % de persones tractades amb Aubagio sense s\u00edmptomes despr\u00e9s de 2 anys - GAEM (Grupo de Afectados de Esclerosis M\u00faltiple)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fundaciongaem.org\/ca\/el-58-de-persones-tractades-amb-aubagio-sense-simptomes-despres-de-2-anys-2\/","og_locale":"ca_ES","og_type":"article","og_title":"El 58 % de persones tractades amb Aubagio sense s\u00edmptomes despr\u00e9s de 2 anys - GAEM (Grupo de Afectados de Esclerosis M\u00faltiple)","og_description":"\u00e1s de la mitad de las personas con esclerosis m\u00faltiple tratadas con Aubagio (teriflunomida) no mostraron evidencia de actividad de la enfermedad despu\u00e9s de dos a\u00f1os de tratamiento","og_url":"https:\/\/fundaciongaem.org\/ca\/el-58-de-persones-tractades-amb-aubagio-sense-simptomes-despres-de-2-anys-2\/","og_site_name":"GAEM (Grupo de Afectados de Esclerosis M\u00faltiple)","article_publisher":"https:\/\/www.facebook.com\/FundacioGaem\/","article_published_time":"2022-07-12T08:22:00+00:00","og_image":[{"width":1024,"height":631,"url":"https:\/\/fundaciongaem.org\/wp-content\/uploads\/2024\/03\/Teriflunomide_3D_ball-1.png","type":"image\/png"}],"author":"PROGRAMADOR","twitter_card":"summary_large_image","twitter_creator":"@fundaciongaem","twitter_site":"@fundaciongaem","twitter_misc":{"Escrit per":"PROGRAMADOR","Temps estimat de lectura":"3 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fundaciongaem.org\/ca\/el-58-de-persones-tractades-amb-aubagio-sense-simptomes-despres-de-2-anys-2\/#article","isPartOf":{"@id":"https:\/\/fundaciongaem.org\/ca\/el-58-de-persones-tractades-amb-aubagio-sense-simptomes-despres-de-2-anys-2\/"},"author":{"name":"PROGRAMADOR","@id":"https:\/\/fundaciongaem.org\/ca\/#\/schema\/person\/093d963705cb588ce96ffe4a15bde10c"},"headline":"El 58 % de persones tractades amb Aubagio sense s\u00edmptomes despr\u00e9s de 2 anys","datePublished":"2022-07-12T08:22:00+00:00","mainEntityOfPage":{"@id":"https:\/\/fundaciongaem.org\/ca\/el-58-de-persones-tractades-amb-aubagio-sense-simptomes-despres-de-2-anys-2\/"},"wordCount":713,"commentCount":0,"publisher":{"@id":"https:\/\/fundaciongaem.org\/ca\/#organization"},"image":{"@id":"https:\/\/fundaciongaem.org\/ca\/el-58-de-persones-tractades-amb-aubagio-sense-simptomes-despres-de-2-anys-2\/#primaryimage"},"thumbnailUrl":"https:\/\/fundaciongaem.org\/wp-content\/uploads\/2024\/03\/Teriflunomide_3D_ball-1.png","keywords":["#esclerosism\u00faltiple","Aubagio","Esclerosis M\u00faltiple","teriflunomida"],"articleSection":["EM \/ NMO"],"inLanguage":"ca"},{"@type":"WebPage","@id":"https:\/\/fundaciongaem.org\/ca\/el-58-de-persones-tractades-amb-aubagio-sense-simptomes-despres-de-2-anys-2\/","url":"https:\/\/fundaciongaem.org\/ca\/el-58-de-persones-tractades-amb-aubagio-sense-simptomes-despres-de-2-anys-2\/","name":"El 58 % de persones tractades amb Aubagio sense s\u00edmptomes despr\u00e9s de 2 anys - GAEM (Grupo de Afectados de Esclerosis M\u00faltiple)","isPartOf":{"@id":"https:\/\/fundaciongaem.org\/ca\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fundaciongaem.org\/ca\/el-58-de-persones-tractades-amb-aubagio-sense-simptomes-despres-de-2-anys-2\/#primaryimage"},"image":{"@id":"https:\/\/fundaciongaem.org\/ca\/el-58-de-persones-tractades-amb-aubagio-sense-simptomes-despres-de-2-anys-2\/#primaryimage"},"thumbnailUrl":"https:\/\/fundaciongaem.org\/wp-content\/uploads\/2024\/03\/Teriflunomide_3D_ball-1.png","datePublished":"2022-07-12T08:22:00+00:00","breadcrumb":{"@id":"https:\/\/fundaciongaem.org\/ca\/el-58-de-persones-tractades-amb-aubagio-sense-simptomes-despres-de-2-anys-2\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fundaciongaem.org\/ca\/el-58-de-persones-tractades-amb-aubagio-sense-simptomes-despres-de-2-anys-2\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/fundaciongaem.org\/ca\/el-58-de-persones-tractades-amb-aubagio-sense-simptomes-despres-de-2-anys-2\/#primaryimage","url":"https:\/\/fundaciongaem.org\/wp-content\/uploads\/2024\/03\/Teriflunomide_3D_ball-1.png","contentUrl":"https:\/\/fundaciongaem.org\/wp-content\/uploads\/2024\/03\/Teriflunomide_3D_ball-1.png","width":1024,"height":631},{"@type":"BreadcrumbList","@id":"https:\/\/fundaciongaem.org\/ca\/el-58-de-persones-tractades-amb-aubagio-sense-simptomes-despres-de-2-anys-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/fundaciongaem.org\/ca\/inicio\/"},{"@type":"ListItem","position":2,"name":"El 58 % de persones tractades amb Aubagio sense s\u00edmptomes despr\u00e9s de 2 anys"}]},{"@type":"WebSite","@id":"https:\/\/fundaciongaem.org\/ca\/#website","url":"https:\/\/fundaciongaem.org\/ca\/","name":"GAEM (Grupo de Afectados de Esclerosis M\u00faltiple)","description":"","publisher":{"@id":"https:\/\/fundaciongaem.org\/ca\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fundaciongaem.org\/ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/fundaciongaem.org\/ca\/#organization","name":"GAEM (Grupo de Afectados de Esclerosis M\u00faltiple)","url":"https:\/\/fundaciongaem.org\/ca\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/fundaciongaem.org\/ca\/#\/schema\/logo\/image\/","url":"https:\/\/fundaciongaem.org\/wp-content\/uploads\/2023\/11\/LOGO-2.png","contentUrl":"https:\/\/fundaciongaem.org\/wp-content\/uploads\/2023\/11\/LOGO-2.png","width":354,"height":132,"caption":"GAEM (Grupo de Afectados de Esclerosis M\u00faltiple)"},"image":{"@id":"https:\/\/fundaciongaem.org\/ca\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/FundacioGaem\/","https:\/\/x.com\/fundaciongaem","https:\/\/www.linkedin.com\/company\/2454646","https:\/\/www.instagram.com\/fundaciongaem\/cebook.com\/FundacioGaem\/","https:\/\/www.youtube.com\/user\/fundaciogaem"]},{"@type":"Person","@id":"https:\/\/fundaciongaem.org\/ca\/#\/schema\/person\/093d963705cb588ce96ffe4a15bde10c","name":"PROGRAMADOR","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/secure.gravatar.com\/avatar\/b57ee1544b5750bf1116758aec83af4d7c9709bbc2131c9e1568d92ff8d2e28b?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b57ee1544b5750bf1116758aec83af4d7c9709bbc2131c9e1568d92ff8d2e28b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b57ee1544b5750bf1116758aec83af4d7c9709bbc2131c9e1568d92ff8d2e28b?s=96&d=mm&r=g","caption":"PROGRAMADOR"},"sameAs":["https:\/\/fundaciongaem.org"],"url":"https:\/\/fundaciongaem.org\/ca\/author\/gaem\/"}]}},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/fundaciongaem.org\/ca\/wp-json\/wp\/v2\/posts\/18707","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fundaciongaem.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fundaciongaem.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fundaciongaem.org\/ca\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/fundaciongaem.org\/ca\/wp-json\/wp\/v2\/comments?post=18707"}],"version-history":[{"count":0,"href":"https:\/\/fundaciongaem.org\/ca\/wp-json\/wp\/v2\/posts\/18707\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fundaciongaem.org\/ca\/wp-json\/wp\/v2\/media\/18237"}],"wp:attachment":[{"href":"https:\/\/fundaciongaem.org\/ca\/wp-json\/wp\/v2\/media?parent=18707"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fundaciongaem.org\/ca\/wp-json\/wp\/v2\/categories?post=18707"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fundaciongaem.org\/ca\/wp-json\/wp\/v2\/tags?post=18707"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}